Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered drugs in the U.S. The company collaborates and has license agreements with Takeda Pharmaceutical Company Ltd, Skysong Innovations LLC, and the University of Minnesota. The company was incorporated in 2014 and is based in Somerville, MA.